Propranolol hydrochloride osmotic capsule with controlled onset of release

Drug Delivery

Volumn 14, Issue 7, 2007, Pages 461-468

  Barzegar Jalali, Mohammad ^a   Adibkia, Khosro ^b   Mohammadi, Ghobad ^c   Zeraati, Mahdi ^d   Bolagh, Behnaz Aghaee Ghare ^d   Nokhodchi, Ali ^e  

^a TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b ZANJAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^e MEDWAY SCHOOL OF PHARMACY   (United Kingdom)

Author keywords

Chronotherapeutic; Controlled Onset of Release; Delayed Release; Osmotic Capsule; Propranolol Hydrochloride

Indexed keywords

CAPSULINE; CASTOR OIL; CELLULOSE ACETATE; GELATIN; OSMOTIC AGENT; PROPOLIS; PROPRANOLOL; SORBITOL; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED DRUG RELEASE; DRUG CAPSULE; DRUG COATING; DRUG FORMULATION; DRUG SOLUBILITY; HEART INFARCTION; HYDROSTATIC PRESSURE; OSMOSIS; PRIORITY JOURNAL; STROKE;

ADRENERGIC BETA-ANTAGONISTS; CAPSULES; CASTOR OIL; CELLULOSE; CHRONOTHERAPY; DELAYED-ACTION PREPARATIONS; EXCIPIENTS; HUMANS; MEMBRANES, ARTIFICIAL; OSMOSIS; PROPRANOLOL; SOLUBILITY; SORBITOL; TIME FACTORS; WAXES;

EID: 36248956162     PISSN: 10717544     EISSN: 15210464     Source Type: Journal    
DOI: 10.1080/10717540701603639     Document Type: Article

References (25)

1. Amidon, G. L., and Leesman, G. D. 1993. Pulsatile drug delivery system. U.S. Patent 5229131.
2. Amidon, G. L., and Leesman, G. D. 1995. Multi-stage drug delivery system. U.S. Patent 5387421.
3. Amidon, G. L., and Leesman, G. D. 1997. Method for making a multi-stage drug delivery system. U.S. Patent 5674530.
4. Bodea, A., and Leucuta, S. E. 1998. Optimization of propranolol hydrochloride sustained-release pellets using box-behnken design and desirability function. Drug Dev. Ind. Pharm. 24:145-155.
5. Dabbagh, M. A., Ford, J. L., Rubinstein, M. H., Hogan, J. E., and Rajabi Siahboomi, A. R. 1999. Release of propranolol hydrochloride from matrix tablets containing sodium carboxymethylcellulose and hydroxypropylmethylcellulose. Pharm. Dev. Technol. 4:313-324.
6. Gosthoskar, A. V., Joshi, A. M., and Joshi, N. H. 2004. Pulsatile drug delivery systems: a review. Drug Del. Tech. 4:1-8.
7. Huang, Y. B., Tsai, Y. H., Yang, W. C., Chang, J. S., and Wu, P. C. 2004a. Optimization of sustained-release propranolol dosage form using factorial design and response surface methodology. Biol. Pharm. Bull. 27:1626-1629.
8. Huang, Y. B., Tsai, Y. H., Yang, W. C., Chang, J. S., Wu, P. C., and Takayama, K. 2004b. Once-daily propranolol extended-release tablet dosage form: formulation design and in vitro/in vivo investigation. Eur. J. Pharm. Biopharm. 58:607-614.
9. Krogel, R., and Bodmeier, R. 1998. Pulsatile drug release from an insoluble capsule body controlled by an erodible plug. Pharm. Res. 15:474-481.
10. Lund, W. 1994. The Pharmaceutical Codex. London: The Pharmaceutical Press, 1025-1029.
11. Mohammadi Samani, S., Adrangui, M., Siahi-Shadbad, M. R., and Nokhodchi, A. 2000. An approach to controlled-release dosage form of propranolol hydrochloride. Drug Dev. Ind. Pharm. 26:91-94.
12. Neutel, J. M., and Rotenberg, K. 2005. Comparison of a chronotherapeutically administered beta blocker vs. a traditionally administered beta blocker in patients with hypertension. J. Clin. Hypertens. 7:395-400.
13. Nokhodchi, A., Norouzi-Sani, S., Siahi Shadbad, M. R. Lotfipoor, F., and Saeedi, M. 2002. The effect of various surfactants on the release rate of propranolol hydrochloride from hydroxypropylmethylcellulose (HPMC)-Eudragit matrices. Eur. J. Pharm. Biopharm. 54:349-356.
14. Prisant, L. M., and Elliott, W. J. 2003. Drug delivery systems for treatment of systemic hypertension. Clin. Pharmacok. 42:931-940.
15. Rekhi, G. S., and Jambhekar, S. S. 1996. Bioavailability and in-vitro/in-vivo correlation for propranolol hydrochloride extended-release bead products prepared using aqueous polymeric dispersions. J. Pharm. Pharmacol. 48:1276-1284.
16. Sadeghi, F., Afrasiabi-Garekani, H., and Goli, F. 2004. Tableting of Eudragit RS and propranolol hydrochloride solid dispersion: effect of particle size, compaction force, and plasticizer addition on drug release. Drug Dev. Ind. Pharm. 30:759-766.
17. Sangalli, M. E., Maroni, A., Zerona, L., Busetti, C., Giordano, F., and Gazzaniga, A. 2001. In vitro and in vivo evaluation of an oral system for time and/or site-specific drug delivery. J. Control. Rel. 73:103-110.
18. Sica, D., Frishman, W. H., and Manowitz, N. 2003. Pharmacokinetics of propranolol after single and multiple dosing with sustained release propranolol or propranolol CR (innopran XL), a new chronotherapeutic formulation. Heart Dis. 5:176-181.
19. Sinko, P. 2006. Nonelectrolytes. In Martin's Physical & Pharmacy Science, 15thed., ed. Sinko P., 119-141. Philadelphia: Lippincott Williams and Wilkins.
20. United States Pharmacopoeia, (USP28) 2005. Rockville, MD: United States Pharmacopoeial Convention.
21. Stavropoulou, A., Papadkostaki, K. G., and Sanopoulou, M. 2005. Experimental and theoretical study of the release kinetics of propranolol hydrochloride from PVA matrices. J. Control. Rel. 101:313-315.
22. Takka, S., Rajbhandari, S., and Sakr, A. 2001. Effect of anionic polymers on the release of propranolol hydrochloride from matrix tablets. Eur. J. Pharm. Biopharm. 52:75-82.
23. Ueda, Y., Hata, T., Yamaguchi, H., Ueda, S., and Kotani, M. 1989. Time controlled explosion system and process for preparation for the same. U.S. Patent 4871549.
24. Varshosaz, J., and Keihanfar, M. 2001. Development and evaluation of sustainedrelease propranolol wax microspheres. J. Microencapsul. 18:277-284.
25. Wilding, I. R., Davis, S. S., Bakhshaee, M. M., Stevens, H. N. E., Sparrow, R. A., and Brenna, J. 1998. Gastrointestinal and systemic absorption of captopril from capsuled-release formulation. Pharm. Res. 9:654-657.